A Phase 2 interventional study of ABX464 100 mg and ABX464 50 mg in Ulcerative Colitis, sponsored by Abivax S.A.. Completed at 130 sites in 17 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-28.
Sponsored by Abivax S.A. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 239 studies in Colitis, Ulcerative with a site in France — 46 open to participants now, 79 under way, 27 of them phase 3. Colitis, Ulcerative · France.
Among the 239 studies in Colitis, Ulcerative with a site in France, this one is the 53rd largest by enrollment of the 184 interventional ones that give a count, is one of 19 that started in 2019, is one of 60 in phase 2, and was the 117th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →46 of the 239 studies in Colitis, Ulcerative with a site in France are open now. Recruiting first, the newest first:
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Sites in France
Ages 18+
Palisade Bio · Sites in France, United States, Canada and 9 more countries
Ages 18–75
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages up to 17
Pfizer · Sites in France, United States, Australia and 7 more countries
Ages 2–11
Janssen Research & Development, LLC · Sites in France, United States, Argentina and 30 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
239 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 71 · Phase 3 73 · Phase 4 14
First in 2003; this study’s year is marked. 19 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 355 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 196 across the 184 interventional studies, 360 across the 55 observational. Of the 150 that completed or were terminated, 71 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
149 of 239 have an industry lead sponsor. The 10 most frequent:
Abivax S.A. is the lead sponsor of 23 studies on the registry; 2 are open to participants now.
Abivax S.A. has 8 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
22 of the studies in Colitis, Ulcerative with a site in France that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
Add all 22 to your calendar (.ics) → With an account.
Among the 239 studies in Colitis, Ulcerative with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Phase 2b study to evaluate the efficacy and the safety of 3 dose-levels of ABX464, administered daily in patients with moderate to severe Ulcerative Colitis.
This phase 2b study will evaluate the efficacy and the safety of 3 dose-levels of ABX464, administered daily in improving Modified Mayo Score (MMS) in patients with moderate to severe Ulcerative Colitis who have inadequate response, loss of response, or intolerance with at least one of the following agents: immunosuppressant treatment (i.e. azathioprine, 6-mercaptopurine, methotrexate), tumor necrosis factor alpha [TNF-α] inhibitors, vedolizumab, JAK inhibitors and/or corticosteroid treatment .
Eligible patients will be randomized into 4 parallel intervention/treatment groups: 100mg q.d of ABX464, 50mg q.d of ABX464, 25mg q.d of ABX464, or matching placebo and will be treated for 16 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients having either a documented inadequate response, no response, a loss of response, or an intolerance (defined as the occurrence of at least one Adverse Reaction leading to treatment discontinuation) to either treatment (i.e., azathioprine, 6-mercaptopurine, methotrexate), tumor necrosis factor [TNF] inhibitors, vedolizumab, JAK inhibitors and/or treatment. Inadequate response, no response, loss of response is defined as:
i. Active disease or relapse in spite of thiopurines or methotrexate given at an appropriate dose for at least 3 months (i.e. azathioprine 2-2.5 mg/kg/day or mercaptopurine 1-1.5 mg/kg/day in the absence of leukopenia), and/or ii. Active disease despite corticosteroids treatment (prednisolone up to 0.75 mg/kg/day) over a period of 4 Weeks, and/or iii. Active disease or relapse in spite of adequate treatment (as defined in the SmPC) with tumor necrosis factor [TNF] inhibitors or vedolizumab, and/or iv. Active disease or relapse in spite of adequate treatment with JAK inhibitors over a period of at least 6 Weeks.
Patients with the following hematological and biochemical laboratory parameters obtained at screening:
i. > 9.0 g dL-1; ii. ≥ 750 mm-3; iii. ≥ 100,000 mm-3; iv. Total serum creatinine ≤ 1.3 x (upper limit of normal); v. > 90 mL min-1 by the Cockcroft-Gault equation within 60 days prior to baseline; vi. Total serum \< 1.5 x ULN; vii. Alkaline phosphatase, (SGOT) and ALT (SGPT) \< 2 x ULN;
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ABX464 100 mg was administered orally (capsules) once daily for 16 weeks
Drug: ABX464 100 mg
ABX464 50 mg was administered orally (capsules) once daily for 16 weeks
Drug: ABX464 50 mg
ABX464 25 mg was administered orally (capsules) once daily for 16 weeks
Drug: ABX464 25 mg
Matching placebo was administered orally (capsules) once daily for 16 weeks
Drug: Placebo
ABX464 100 mg (two capsules of ABX464 50 mg) once daily for 16 weeks
Also known as: Obefazimod 100 mg
ABX464 50 mg (one capsule of ABX464 50 mg + one capsule of placebo) once daily for 16 weeks
Also known as: Obefazimod 50 mg
ABX464 25 mg (one capsule of ABX464 25 mg + one capsule of placebo) once daily for 16 weeks
Also known as: Obefazimod 25 mg
Two capsules of placebo once daily for 16 weeks
Also known as: Obefazimod placebo control
Reduction From Baseline in Modified Mayo Score (MMS) at Week 8
Reduction from baseline in Modified Mayo Score (MMS) MMS is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall MMS ranges from 0 to 9 where higher scores represent more severe disease.
Time frame: Week 8
Reduction From Baseline in MMS at Week 16
Reduction from baseline in Modified Mayo Score (MMS) MMS is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall MMS ranges from 0 to 9 where higher scores represent more severe disease.
Time frame: Week 16
Number of Participants in Clinical Remission Per MMS at Week 8
Number of participants who achieved clinical remission per Modified Mayo Score at Week 8 MMS is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall MMS ranges from 0 to 9 where higher scores represent more severe disease. Clinical remission is defined as SFS ≤ 1, RBS of 0, and endoscopic subscore ≤ 1 (modified to exclude friability)
Time frame: Week 8
Number of Participants in Clinical Remission Per MMS at Week 16
Number of participants who achieved clinical remission per Modified Mayo Score at Week 16 MMS is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall MMS ranges from 0 to 9 where higher scores represent more severe disease. Clinical remission is defined as SFS ≤ 1, RBS of 0, and endoscopic subscore ≤ 1 (modified to exclude friability)
Time frame: Week 16
Number of Participants With Clinical Response at Week 8
Clinical response is defined as a reduction in MMS of at least 2 points and greater than or equal to 30 percent from baseline with an accompanying decrease in rectal bleeding sub-score of greater than or equal to 1 point or absolute rectal bleeding sub-score of less than or equal to 1 point.
Time frame: Week 8
Number of Participants With Clinical Response at Week 16
Clinical response is defined as a reduction in MMS of at least 2 points and greater than or equal to 30 percent from baseline with an accompanying decrease in rectal bleeding sub-score of greater than or equal to 1 point or absolute rectal bleeding sub-score of less than or equal to 1 point.
Time frame: Week 16
Number of Participants With Endoscopic Improvement at Week 8
Endoscopic improvement is defined as an endoscopic subscore of 0 or 1 (excluding friability) Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1. = Mild disease (erythema, decreased vascular pattern); 2. = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3. = Severe disease (spontaneous bleeding, ulceration). A higher endoscopic score indicates more severe disease.
Time frame: Week 8
Number of Participants With Endoscopic Improvement at Week 16
Endoscopic improvement is defined as an endoscopic subscore of 0 or 1 (excluding friability) Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1. = Mild disease (erythema, decreased vascular pattern); 2. = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3. = Severe disease (spontaneous bleeding, ulceration). A higher endoscopic score indicates more severe disease.
Time frame: Week 16
Number of Participants With Mucosal Healing at Week 8
Mucosal healing is defined as endoscopic remission (overall mucosal appearance at endoscopy subscore=0) and histological remission (Geboes score \<2.0 based on rectal biopsy). The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration. A higher score is associated with higher disease activity.
Time frame: Week 8
Number of Participants With Mucosal Healing at Week 16
Mucosal healing is defined as endoscopic remission (overall mucosal appearance at endoscopy subscore=0) and histological remission (Geboes score \<2.0 based on rectal biopsy). The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration. A higher score is associated with higher disease activity.
Time frame: Week 16
Number of Participants With Reduction of Stool Frequency Relative to Baseline (Day 1)
Participants recorded stool frequency using an electronic subject diary on a daily basis. The stool frequency subscore (SFS) ranges from 0 to 3 according to the following scale: Score 0: Normal number of stools Score 1: 1 to 2 stools per day more than normal Score 2: 3 to 4 stools per day more than normal Score 3: 5 or more stools per day more than normal Decreasing score indicates improvement.
Time frame: Day 8, Day 29, Day 57, Day 85, Day 113, and Day 120 (End of Study)
Number of Participants With Reduction of Rectal Bleeding Frequency Relative to Baseline
Participants recorded rectal bleeding in an electronic subject diary on a daily basis. Rectal bleeding score (RBS) is taken as the worst subscore of the three most recent scores within 7 days prior to the visit. The rectal bleeding subscore ranges from 0 to 3 according to the following scale: Score 0: No blood seen Score 1: Streaks of blood with stool less than half the time Score 2: Obvious blood with stool most of the time Score 3: Blood alone passed A lower score represents an improvement in rectal bleeding.
Time frame: Day 8, Day 29, Day 57, Day 85, Day 113, and Day 120 (End of Study)
Partial Modified Mayo Score Change From Baseline
Partial Modified Mayo Score (pMMS) Change from baseline The pMMS is a composite score of UC disease activity based on the following 2 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools per day) to 3 (5 or more stools per day more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). The overall pMMS score ranges from 0 to 6 with higher scores representing more severe disease.
Time frame: Day 8, Day 29, Day 57, Day 85, Day 113, and Day 120 (End of Study)
Number of Participants With Reduction Relative to Baseline in Fecal Calprotectin at Weeks 8 and 16
Fecal Calprotectin (FC) is a non-invasive surrogate marker of inflammation in the small intestine and levels below 250 ug/g is associated with mucosal healing. FC levels were measured using enzyme-linked immunosorbent assay (ELISA) and/or a validated quantitative rapid test. Outcome will be measured based on a reduction in FC relative to baseline values.
Time frame: Week 8 and Week 16
Number of Participants With Reduction Relative to Baseline in C Reactive Protein at Weeks 8 and 16
CRP is an acute-phase protein which provides an objective criterion of inflammatory activity. CRP has a short half-life (19 hours) and therefore rises early after the onset of inflammation and rapidly decreases after resolution of the inflammation. It is induced by interleukin-6, TNF-alpha and other pro-inflammatory cytokines that are produced within the intestinal lamina propria. Outcome will be measured based on a reduction in CRP relative to baseline values.
Time frame: Week 8 and Week 16
miRNA-124 Expression (Copy Number) in Whole Blood at Week 8 and Week 16
Absolute quantification (QuantaSoft Pro) of the miR-124 copy number was performed at Week 8 and Week 16 using droplet digital PCR technology (ddPCR) on whole blood samples. "0" in the placebo column means "no signal", so BLQ (Below the level of quantification).
Time frame: Week 8 and Week 16
IL-6 Serum Concentrations
Serum samples from participants who received ABX464 (25, 50 or 100 mg) or placebo were collected during 5 visits (Day 1, Day 8, Day 29, Day 57, and Day 113). IL6 was measured using the 8-plex assay on the ELLA Platform (Biotechne). All samples were tested in duplicate at the minimum required dilution. Baseline (Day 1) values are calculated as below: x1/arithmetic mean of baseline values x 100, where the arithmetic mean is defined by (x1 + x2+...+xn)/n (summing all baseline values and dividing by the total number of values n) The post baseline values are calculated as follow: post-baseline IL-6 values - Day 1 IL-6 values/Day 1 IL-6 values)\*100
Time frame: Day 1
Number of Participants With Endoscopic Remission at Week 8
Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1. = Mild disease (erythema, decreased vascular pattern); 2. = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3. = Severe disease (spontaneous bleeding, ulceration). A higher score represents more severe disease.
Time frame: Week 8
Number of Participants With Endoscopic Remission at Week 16
Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1. = Mild disease (erythema, decreased vascular pattern); 2. = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3. = Severe disease (spontaneous bleeding, ulceration). A higher score represents more severe disease.
Time frame: Week 16
IL-10 Serum Concentrations
Serum samples from patients who received ABX464 (25, 50 or 100 mg) or placebo were collected during 5 visits (Day 1, Day 8, Day 29, Day 57, and Day 113). IL10 was measured using the 8-plex assay on the ELLA Platform. All samples were tested in duplicate at the minimum required dilution. Baseline (Day 1) values are calculated as below: x1/arithmetic mean of baseline values x 100, where the arithmetic mean is defined by (x1 + x2+...+xn)/n (summing all baseline values and dividing by the total number of values n) The post baseline values are calculated as follow: post-baseline IL-10 values - Day 1 IL-10 values/Day 1 IL-10 values)\*100
Time frame: Day 1
IL-1B Serum Concentrations
Serum samples from patients who received ABX464 (25, 50, or 100 mg) or placebo were collected during 5 visits (Day 1, Day 8, Day 29, Day 57 and Day 113). IL1beta was measured using the 8-plex assay on the ELLA Platform. All samples were tested in duplicate at the minimum required dilution. Baseline (Day 1) values are calculated as below: x1/arithmetic mean of baseline values x 100, where the arithmetic mean is defined by (x1 + x2+...+xn)/n (summing all baseline values and dividing by the total number of values n) The post baseline values are calculated as follow: post-baseline IL-1B values - Day 1 IL-1B values/Day 1 IL-1B values)\*100
Time frame: Day 1
TNFα Serum Concentrations
Serum samples from patients who received ABX464 (25, 50, or 100 mg) or placebo were collected during 5 visits (Day 1, Day 8, Day 29, Day 57 and Day 113 TNF-alpha was measured using the 8-plex assay on the ELLA Platform. All samples were tested in duplicate at the minimum required dilution. Baseline (Day 1) values are calculated as below: x1/arithmetic mean of baseline values x 100, where the arithmetic mean is defined by (x1 + x2+...+xn)/n (summing all baseline values and dividing by the total number of values n) The post baseline values are calculated as follow: post-baseline TNFα values - Day 1 TNFα values/Day 1 TNFα values)\*100
Time frame: Day 1
Change From Baseline in Infiltrate/Histopathology Using Robarts Histopathology Index (RHI) at Week 8 and Week 16
Infiltrate/Histopathology (Rectal/Sigmoidal Biopsies) using the Robarts Histopathology Index (RHI) Week 8 and Week 16 biopsies will be compared to biopsies at baseline to assess the disease evolution at a tissue level, based on the Robarts Histological Index. The score ranges from 0 (no disease activity) to 33 (severe disease activity) is based on evaluation of 4 parameters: chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in the epithelium and erosion and ulceration. A higher score indicates more severe disease.
Time frame: Week 8 and Week 16
Change From Baseline in Infiltrate/Histopathology - Geboes Score at Week 8 and Week 16
The Geboes score is composed of 6 major grades that assess different aspects of the biopsy findings, with each grade having its own score range: 1. Structural Changes (Grade 0): Range: 0 (No changes) to 3 (Severe changes) 2. Chronic Inflammation (Grade 1): Range: 0 (No inflammation) to 3 (Severe inflammation) 3. Lamina Propria Neutrophils (Grade 2): Range: 0 (None) to 3 (Severe infiltration of neutrophils) 4. Neutrophils in the Epithelium (Grade 3): Range: 0 (None) to 3 (Severe neutrophil infiltration) 5. Crypt Destruction (Grade 4): Range: 0 (No destruction) to 3 (Severe crypt destruction) 6. Erosion and Ulcers (Grade 5): Range: 0 (None) to 3 (Severe erosion/ulceration) Subscales are summed across all 6 grades, final total score between 0 and 18 : * 0-5: Minimal or no inflammation * 6-10: Mild inflammation * 11-15: Moderate inflammation * 16-18: Severe inflammation or damage A higher score indicates more severe disease
Time frame: Week 8 and Week 16
IL-6 Serum Concentrations
Serum samples from participants who received ABX464 (25, 50 or 100 mg) or placebo were collected during 5 visits (Day 1, Day 8, Day 29, Day 57, and Day 113). IL6 was measured using the 8-plex assay on the ELLA Platform (Biotechne). All samples were tested in duplicate at the minimum required dilution. Baseline (Day 1) values are calculated as below: x1/arithmetic mean of baseline values x 100, where the arithmetic mean is defined by (x1 + x2+...+xn)/n (summing all baseline values and dividing by the total number of values n) The post baseline values are calculated as follow: post-baseline IL-6 values - Day 1 IL-6 values/Day 1 IL-6 values)\*100
Time frame: Day 8, Day 29, Day 57, and Day 113
IL-10 Serum Concentrations
Serum samples from patients who received ABX464 (25, 50 or 100 mg) or placebo were collected during 5 visits (Day 1, Day 8, Day 29, Day 57, and Day 113). IL10 was measured using the 8-plex assay on the ELLA Platform. All samples were tested in duplicate at the minimum required dilution. Baseline (Day 1) values are calculated as below: x1/arithmetic mean of baseline values x 100, where the arithmetic mean is defined by (x1 + x2+...+xn)/n (summing all baseline values and dividing by the total number of values n) The post baseline values are calculated as follow: post-baseline IL-10 values - Day 1 IL-10 values/Day 1 IL-10 values)\*100
Time frame: Day 8, Day 29, Week 8 and Week 16
IL-1B Serum Concentrations
Serum samples from patients who received ABX464 (25, 50, or 100 mg) or placebo were collected during 5 visits (Day 1, Day 8, Day 29, Day 57 and Day 113). IL1beta was measured using the 8-plex assay on the ELLA Platform. All samples were tested in duplicate at the minimum required dilution. Baseline (Day 1) values are calculated as below: x1/arithmetic mean of baseline values x 100, where the arithmetic mean is defined by (x1 + x2+...+xn)/n (summing all baseline values and dividing by the total number of values n) The post baseline values are calculated as follow: post-baseline IL-1B values - Day 1 IL-1B values/Day 1 IL-1B values)\*100
Time frame: Day 8, Day 29, Day 57 and Day 113
TNFα Serum Concentrations
Serum samples from patients who received ABX464 (25, 50, or 100 mg) or placebo were collected during 5 visits (Day 1, Day 8, Day 29, Day 57 and Day 113 TNF-alpha was measured using the 8-plex assay on the ELLA Platform. All samples were tested in duplicate at the minimum required dilution. Baseline (Day 1) values are calculated as below: x1/arithmetic mean of baseline values x 100, where the arithmetic mean is defined by (x1 + x2+...+xn)/n (summing all baseline values and dividing by the total number of values n) The post baseline values are calculated as follow: post-baseline TNFα values - Day 1 TNFα values/Day 1 TNFα values)\*100
Time frame: Day 8, Day 29, Day 57 and Day 113
A total of 355 patients consented to participate, 254 patients were randomized. A total of 253 patients were treated, 222 patients completed study treatment. 32 patients discontinued and 1 patient was randomized but did not receive study drug. One further patient was excluded from the Full Analysis Set (FAS) due to noncompliance with inclusion/exclusion criteria. A total of 252 patients were included in the FAS (64: ABX464 100mg q.d, 63: ABX464 50mg q.d, 61: ABX464 25mg q.d and 64: placebo).
| Milestone | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| Started | 64 | 63 | 63 | 64 |
| Treated | 64 | 63 | 62 | 64 |
| Full analysis set | 64 | 63 | 61 | 64 |
| Completed | 54 | 53 | 58 | 57 |
| Not completed | 10 | 10 | 5 | 7 |
Reduction from baseline in Modified Mayo Score (MMS) MMS is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall MMS ranges from 0 to 9 where higher scores represent more severe disease.
| Score | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| Reduction From Baseline in Modified Mayo Score (MMS) at Week 8 | -2.9 (-3.4 to -2.5) | -3.2 (-3.7 to -2.7) | -3.1 (-3.6 to -2.6) | -1.9 (-2.4 to -1.5) |
Reduction from baseline in Modified Mayo Score (MMS) MMS is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall MMS ranges from 0 to 9 where higher scores represent more severe disease.
| Score | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| Overall | -3.6 (-4.3 to -2.9) | -3.2 (-3.9 to -2.5) | -3.3 (-3.9 to -2.7) | -2.4 (-2.9 to -1.8) |
| With Previous Biologics or JAK Inhibitors Exposure | -3.3 (-4.1 to -2.6) | -3.0 (-3.9 to -2.1) | -2.9 (-3.7 to -2.1) | -1.3 (-2.0 to -0.5) |
| Without Previous Biologics or JAK Inhibitors Exposure | -3.6 (-4.8 to -2.3) | -3.4 (-4.4 to -2.5) | -3.7 (-4.6 to -2.8) | -3.4 (-4.2 to -2.6) |
Number of participants who achieved clinical remission per Modified Mayo Score at Week 8 MMS is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall MMS ranges from 0 to 9 where higher scores represent more severe disease. Clinical remission is defined as SFS ≤ 1, RBS of 0, and endoscopic subscore ≤ 1 (modified to exclude friability)
| Participants | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| Number of Participants in Clinical Remission Per MMS at Week 8 | 16 | 11 | 16 | 8 |
Number of participants who achieved clinical remission per Modified Mayo Score at Week 16 MMS is a composite score of UC disease activity based on the following 3 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). 3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration). The overall MMS ranges from 0 to 9 where higher scores represent more severe disease. Clinical remission is defined as SFS ≤ 1, RBS of 0, and endoscopic subscore ≤ 1 (modified to exclude friability)
| Participants | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| Number of Participants in Clinical Remission Per MMS at Week 16 | 7 | 6 | 9 | 6 |
Clinical response is defined as a reduction in MMS of at least 2 points and greater than or equal to 30 percent from baseline with an accompanying decrease in rectal bleeding sub-score of greater than or equal to 1 point or absolute rectal bleeding sub-score of less than or equal to 1 point.
| Participants | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| Number of Participants With Clinical Response at Week 8 | 32 | 37 | 38 | 22 |
Clinical response is defined as a reduction in MMS of at least 2 points and greater than or equal to 30 percent from baseline with an accompanying decrease in rectal bleeding sub-score of greater than or equal to 1 point or absolute rectal bleeding sub-score of less than or equal to 1 point.
| Participants | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| Number of Participants With Clinical Response at Week 16 | 19 | 20 | 25 | 20 |
Endoscopic improvement is defined as an endoscopic subscore of 0 or 1 (excluding friability) Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1. = Mild disease (erythema, decreased vascular pattern); 2. = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3. = Severe disease (spontaneous bleeding, ulceration). A higher endoscopic score indicates more severe disease.
| Participants | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| Number of Participants With Endoscopic Improvement at Week 8 | 24 | 21 | 20 | 8 |
Endoscopic improvement is defined as an endoscopic subscore of 0 or 1 (excluding friability) Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1. = Mild disease (erythema, decreased vascular pattern); 2. = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3. = Severe disease (spontaneous bleeding, ulceration). A higher endoscopic score indicates more severe disease.
| Participants | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| Number of Participants With Endoscopic Improvement at Week 16 | 11 | 12 | 11 | 9 |
Mucosal healing is defined as endoscopic remission (overall mucosal appearance at endoscopy subscore=0) and histological remission (Geboes score \<2.0 based on rectal biopsy). The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration. A higher score is associated with higher disease activity.
| Participants | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| Number of Participants With Mucosal Healing at Week 8 | 0 | 1 | 0 | 2 |
Mucosal healing is defined as endoscopic remission (overall mucosal appearance at endoscopy subscore=0) and histological remission (Geboes score \<2.0 based on rectal biopsy). The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration). The Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration. A higher score is associated with higher disease activity.
| Participants | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| Number of Participants With Mucosal Healing at Week 16 | 1 | 0 | 0 | 0 |
Participants recorded stool frequency using an electronic subject diary on a daily basis. The stool frequency subscore (SFS) ranges from 0 to 3 according to the following scale: Score 0: Normal number of stools Score 1: 1 to 2 stools per day more than normal Score 2: 3 to 4 stools per day more than normal Score 3: 5 or more stools per day more than normal Decreasing score indicates improvement.
| Participants | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| Day 8 | 18 | 22 | 14 | 12 |
| Day 29 | 34 | 36 | 35 | 26 |
| Week 8 (Day 57) | 39 | 37 | 39 | 37 |
| Day 85 | 41 | 39 | 37 | 30 |
| Week 16 (Day 113) | 44 | 39 | 42 | 38 |
| End of study (Day 120) | 3 | 4 | 1 | 1 |
Participants recorded rectal bleeding in an electronic subject diary on a daily basis. Rectal bleeding score (RBS) is taken as the worst subscore of the three most recent scores within 7 days prior to the visit. The rectal bleeding subscore ranges from 0 to 3 according to the following scale: Score 0: No blood seen Score 1: Streaks of blood with stool less than half the time Score 2: Obvious blood with stool most of the time Score 3: Blood alone passed A lower score represents an improvement in rectal bleeding.
| Participants | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| Day 8 | 25 | 23 | 24 | 16 |
| Day 29 | 44 | 38 | 39 | 24 |
| Week 8 (Day 57) | 48 | 44 | 46 | 33 |
| Day 85 | 47 | 39 | 44 | 35 |
| Week 16 (Day 113) | 50 | 45 | 46 | 37 |
| End of study (Day 120) | 3 | 4 | 1 | 1 |
Partial Modified Mayo Score (pMMS) Change from baseline The pMMS is a composite score of UC disease activity based on the following 2 subscores: 1. Stool frequency subscore (SFS), scored from 0 (normal number of stools per day) to 3 (5 or more stools per day more than normal). 2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed). The overall pMMS score ranges from 0 to 6 with higher scores representing more severe disease.
| Score | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| Day 8 | -0.7 (-1.0 to -0.3) | -0.8 (-1.1 to -0.4) | -0.7 (-1.0 to -0.4) | -0.4 (-0.7 to -0.1) |
| Day 29 | -1.8 (-2.1 to -1.5) | -1.8 (-2.2 to -1.5) | -1.8 (-2.1 to -1.4) | -0.9 (-1.3 to -0.6) |
| Week 8 (Day 57) | -2.2 (-2.6 to -1.9) | -2.2 (-2.5 to -1.9) | -2.3 (-2.6 to -2.0) | -1.6 (-1.9 to -1.3) |
| Day 85 | -2.4 (-2.8 to -2.1) | -2.3 (-2.6 to -2.0) | -2.3 (-2.7 to -2.0) | -1.6 (-1.9 to -1.3) |
| Week 16 (Day 113) | -2.8 (-3.1 to -2.4) | -2.4 (-2.8 to -2.1) | -2.6 (-3.0 to -2.3) | -2.0 (-2.3 to -1.7) |
| End of Study (Day 120) | -1.1 (-2.1 to -0.2) | -1.9 (-2.9 to -1.0) | -3.3 (-5.7 to -0.9) | -1.2 (-2.9 to 0.5) |
Fecal Calprotectin (FC) is a non-invasive surrogate marker of inflammation in the small intestine and levels below 250 ug/g is associated with mucosal healing. FC levels were measured using enzyme-linked immunosorbent assay (ELISA) and/or a validated quantitative rapid test. Outcome will be measured based on a reduction in FC relative to baseline values.
| Participants | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| Week 8 | 33 | 35 | 33 | 26 |
| Week 16 | 37 | 35 | 37 | 22 |
CRP is an acute-phase protein which provides an objective criterion of inflammatory activity. CRP has a short half-life (19 hours) and therefore rises early after the onset of inflammation and rapidly decreases after resolution of the inflammation. It is induced by interleukin-6, TNF-alpha and other pro-inflammatory cytokines that are produced within the intestinal lamina propria. Outcome will be measured based on a reduction in CRP relative to baseline values.
| Participants | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| Week 8 (Day 57) | 31 | 28 | 39 | 29 |
| Week 16 (Day 113) | 31 | 29 | 37 | 29 |
Absolute quantification (QuantaSoft Pro) of the miR-124 copy number was performed at Week 8 and Week 16 using droplet digital PCR technology (ddPCR) on whole blood samples. "0" in the placebo column means "no signal", so BLQ (Below the level of quantification).
| copies number/cell | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| Week 8 | 13753 ± 12142 | 8517 ± 6252 | 4598 ± 11348 | 28.93 ± 146.4 |
| Week 16 | 13268 ± 11134 | 7723 ± 7477 | 4154 ± 5273 | 23.79 ± 94.69 |
Serum samples from participants who received ABX464 (25, 50 or 100 mg) or placebo were collected during 5 visits (Day 1, Day 8, Day 29, Day 57, and Day 113). IL6 was measured using the 8-plex assay on the ELLA Platform (Biotechne). All samples were tested in duplicate at the minimum required dilution. Baseline (Day 1) values are calculated as below: x1/arithmetic mean of baseline values x 100, where the arithmetic mean is defined by (x1 + x2+...+xn)/n (summing all baseline values and dividing by the total number of values n) The post baseline values are calculated as follow: post-baseline IL-6 values - Day 1 IL-6 values/Day 1 IL-6 values)\*100
| Percentage of IL-6 | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| IL-6 Serum Concentrations | 100 ± 10.77 | 100 ± 13.36 | 100 ± 19.37 | 100 ± 28.77 |
Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1. = Mild disease (erythema, decreased vascular pattern); 2. = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3. = Severe disease (spontaneous bleeding, ulceration). A higher score represents more severe disease.
| Participants | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| Number of Participants With Endoscopic Remission at Week 8 | 2 | 5 | 4 | 5 |
Endoscopic remission is defined as an endoscopic subscore of 0. Endoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1. = Mild disease (erythema, decreased vascular pattern); 2. = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3. = Severe disease (spontaneous bleeding, ulceration). A higher score represents more severe disease.
| Participants | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| Number of Participants With Endoscopic Remission at Week 16 | 1 | 1 | 2 | 3 |
Serum samples from patients who received ABX464 (25, 50 or 100 mg) or placebo were collected during 5 visits (Day 1, Day 8, Day 29, Day 57, and Day 113). IL10 was measured using the 8-plex assay on the ELLA Platform. All samples were tested in duplicate at the minimum required dilution. Baseline (Day 1) values are calculated as below: x1/arithmetic mean of baseline values x 100, where the arithmetic mean is defined by (x1 + x2+...+xn)/n (summing all baseline values and dividing by the total number of values n) The post baseline values are calculated as follow: post-baseline IL-10 values - Day 1 IL-10 values/Day 1 IL-10 values)\*100
| Percentage of IL-10 | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| IL-10 Serum Concentrations | 100 ± 8.982 | 100 ± 6.989 | 100 ± 18.98 | 100 ± 17.54 |
Serum samples from patients who received ABX464 (25, 50, or 100 mg) or placebo were collected during 5 visits (Day 1, Day 8, Day 29, Day 57 and Day 113). IL1beta was measured using the 8-plex assay on the ELLA Platform. All samples were tested in duplicate at the minimum required dilution. Baseline (Day 1) values are calculated as below: x1/arithmetic mean of baseline values x 100, where the arithmetic mean is defined by (x1 + x2+...+xn)/n (summing all baseline values and dividing by the total number of values n) The post baseline values are calculated as follow: post-baseline IL-1B values - Day 1 IL-1B values/Day 1 IL-1B values)\*100
| Percentage of IL-1B | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| IL-1B Serum Concentrations | 100 ± 6.514 | 100 ± 8.988 | 100 ± 7.043 | 100 ± 4.87 |
Serum samples from patients who received ABX464 (25, 50, or 100 mg) or placebo were collected during 5 visits (Day 1, Day 8, Day 29, Day 57 and Day 113 TNF-alpha was measured using the 8-plex assay on the ELLA Platform. All samples were tested in duplicate at the minimum required dilution. Baseline (Day 1) values are calculated as below: x1/arithmetic mean of baseline values x 100, where the arithmetic mean is defined by (x1 + x2+...+xn)/n (summing all baseline values and dividing by the total number of values n) The post baseline values are calculated as follow: post-baseline TNFα values - Day 1 TNFα values/Day 1 TNFα values)\*100
| Percentage of TNFα | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| TNFα Serum Concentrations | 100 ± 18.79 | 100 ± 9.313 | 100 ± 19 | 100 ± 5.473 |
Infiltrate/Histopathology (Rectal/Sigmoidal Biopsies) using the Robarts Histopathology Index (RHI) Week 8 and Week 16 biopsies will be compared to biopsies at baseline to assess the disease evolution at a tissue level, based on the Robarts Histological Index. The score ranges from 0 (no disease activity) to 33 (severe disease activity) is based on evaluation of 4 parameters: chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in the epithelium and erosion and ulceration. A higher score indicates more severe disease.
| score on a scale | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| Week 8 | -7.3 (-9.9 to -4.8) | -5.9 (-8.5 to -3.3) | -7.3 (-9.7 to -4.9) | -3.4 (-5.8 to -1.0) |
| Week 16 | -7.6 (-11.2 to -4.0) | -5.8 (-10.0 to -1.6) | -8.0 (-11.2 to -4.7) | -2.8 (-5.9 to 0.3) |
The Geboes score is composed of 6 major grades that assess different aspects of the biopsy findings, with each grade having its own score range: 1. Structural Changes (Grade 0): Range: 0 (No changes) to 3 (Severe changes) 2. Chronic Inflammation (Grade 1): Range: 0 (No inflammation) to 3 (Severe inflammation) 3. Lamina Propria Neutrophils (Grade 2): Range: 0 (None) to 3 (Severe infiltration of neutrophils) 4. Neutrophils in the Epithelium (Grade 3): Range: 0 (None) to 3 (Severe neutrophil infiltration) 5. Crypt Destruction (Grade 4): Range: 0 (No destruction) to 3 (Severe crypt destruction) 6. Erosion and Ulcers (Grade 5): Range: 0 (None) to 3 (Severe erosion/ulceration) Subscales are summed across all 6 grades, final total score between 0 and 18 : * 0-5: Minimal or no inflammation * 6-10: Mild inflammation * 11-15: Moderate inflammation * 16-18: Severe inflammation or damage A higher score indicates more severe disease
| Score change from baseline | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| Week 8 | -4.8 (-6.3 to -3.3) | -3.3 (-4.9 to -1.8) | -4.1 (-5.6 to -2.7) | -1.9 (-3.4 to -0.5) |
| Week 16 | -4.4 (-6.5 to -2.3) | -3.9 (-6.3 to -1.5) | -4.7 (-6.6 to -2.8) | -1.3 (-3.1 to 0.5) |
Serum samples from participants who received ABX464 (25, 50 or 100 mg) or placebo were collected during 5 visits (Day 1, Day 8, Day 29, Day 57, and Day 113). IL6 was measured using the 8-plex assay on the ELLA Platform (Biotechne). All samples were tested in duplicate at the minimum required dilution. Baseline (Day 1) values are calculated as below: x1/arithmetic mean of baseline values x 100, where the arithmetic mean is defined by (x1 + x2+...+xn)/n (summing all baseline values and dividing by the total number of values n) The post baseline values are calculated as follow: post-baseline IL-6 values - Day 1 IL-6 values/Day 1 IL-6 values)\*100
| Percent Change | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| Day 8 | 166.4 ± 20.98 | 96.45 ± 9.034 | 103.6 ± 8.641 | 132.7 ± 15.18 |
| Day 29 | 117 ± 10.92 | 93.36 ± 12.19 | 89.31 ± 8.608 | 128.2 ± 10.85 |
| Week 8 (Day 57) | 118.9 ± 11.3 | 150.6 ± 47.06 | 89.75 ± 8.662 | 125.7 ± 17.11 |
| Week 16 (Day 113) | 108.3 ± 14.23 | 170.1 ± 56.4 | 98.29 ± 12.03 | 131.8 ± 16.97 |
Serum samples from patients who received ABX464 (25, 50 or 100 mg) or placebo were collected during 5 visits (Day 1, Day 8, Day 29, Day 57, and Day 113). IL10 was measured using the 8-plex assay on the ELLA Platform. All samples were tested in duplicate at the minimum required dilution. Baseline (Day 1) values are calculated as below: x1/arithmetic mean of baseline values x 100, where the arithmetic mean is defined by (x1 + x2+...+xn)/n (summing all baseline values and dividing by the total number of values n) The post baseline values are calculated as follow: post-baseline IL-10 values - Day 1 IL-10 values/Day 1 IL-10 values)\*100
| Percent Change | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| Day 8 | 100.3 ± 4.596 | 102.3 ± 5.827 | 101 ± 4.288 | 100.1 ± 3.918 |
| Day 29 | 98.71 ± 6.626 | 87.22 ± 3.638 | 91.40 ± 4.519 | 102.5 ± 4.728 |
| Week 8 (Day 57) | 96.00 ± 5.590 | 99.30 ± 7.431 | 89.30 ± 4.289 | 94.18 ± 4.886 |
| Week 16 (Day 113) | 103.9 ± 7.435 | 92.50 ± 4.879 | 91.24 ± 4.911 | 91.85 ± 5.943 |
Serum samples from patients who received ABX464 (25, 50, or 100 mg) or placebo were collected during 5 visits (Day 1, Day 8, Day 29, Day 57 and Day 113). IL1beta was measured using the 8-plex assay on the ELLA Platform. All samples were tested in duplicate at the minimum required dilution. Baseline (Day 1) values are calculated as below: x1/arithmetic mean of baseline values x 100, where the arithmetic mean is defined by (x1 + x2+...+xn)/n (summing all baseline values and dividing by the total number of values n) The post baseline values are calculated as follow: post-baseline IL-1B values - Day 1 IL-1B values/Day 1 IL-1B values)\*100
| Percent Change | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| Day 8 | 102.8 ± 7.453 | 118.2 ± 10.44 | 103.7 ± 5.562 | 111 ± 5.203 |
| Day 29 | 115 ± 9.424 | 101.3 ± 5.435 | 138 ± 41.41 | 112.6 ± 7.052 |
| Week 8 (Day 57) | 105.3 ± 5.735 | 100.3 ± 6.49 | 99 ± 6.605 | 124.1 ± 12.24 |
| Week 16 (Day 113) | 102.4 ± 6.513 | 137.5 ± 26.11 | 124.1 ± 12.24 | 109 ± 7.042 |
Serum samples from patients who received ABX464 (25, 50, or 100 mg) or placebo were collected during 5 visits (Day 1, Day 8, Day 29, Day 57 and Day 113 TNF-alpha was measured using the 8-plex assay on the ELLA Platform. All samples were tested in duplicate at the minimum required dilution. Baseline (Day 1) values are calculated as below: x1/arithmetic mean of baseline values x 100, where the arithmetic mean is defined by (x1 + x2+...+xn)/n (summing all baseline values and dividing by the total number of values n) The post baseline values are calculated as follow: post-baseline TNFα values - Day 1 TNFα values/Day 1 TNFα values)\*100
| Percent Change | ABX464 100 mg | ABX464 50 mg | ABX464 25 mg | Matching Placebo |
|---|---|---|---|---|
| Day 8 | 98.8 ± 3.423 | 96.77 ± 5.844 | 96.42 ± 4.552 | 99.7 ± 2.739 |
| Day 29 | 99.62 ± 5.374 | 91.30 ± 4.676 | 92.64 ± 4.629 | 110.2 ± 10.12 |
| Week 8 (Day 57) | 105.5 ± 9.675 | 95.55 ± 4.503 | 97.51 ± 4.874 | 102.6 ± 4.873 |
| Week 16 (Day 113) | 103.7 ± 7.610 | 108.6 ± 10.61 | 100.1 ± 7.194 | 111.4 ± 7.725 |
Collected over TEAEs and SAEs were collected from enrollment to end of study: up to 24 weeks in total, including 4 weeks screening (prior the first dose of study drug), 16 weeks of treatment, and 4 weeks safety follow-up (28 days after last dose of study drug). All-cause mortality was reported from enrollment to end of study: up to 24 weeks in total, including 4 weeks screening (prior the first dose of study drug), 16 weeks of treatment, and 4 weeks safety follow-up (28 days after last dose of study drug).. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ABX464, 100mg | 0/64 (0%) | 4/64 (6.3%) | 45/64 (70.3%) |
| ABX464, 50 mg | 0/63 (0%) | 4/63 (6.3%) | 38/63 (60.3%) |
| ABX464, 25mg | 0/62 (0%) | 1/62 (1.6%) | 33/62 (53.2%) |
| Matching Placebo | 0/64 (0%) | 4/64 (6.3%) | 30/64 (46.9%) |
| Event | ABX464, 100mg | ABX464, 50 mg | ABX464, 25mg | Matching Placebo |
|---|---|---|---|---|
| Colitis ulcerativeGastrointestinal disorders | 1/64 | 1/63 | 0/62 | 3/64 |
| AnaemiaBlood and lymphatic system disorders | 0/64 | 0/63 | 1/62 | 0/64 |
| Abdominal painGastrointestinal disorders | 0/64 | 1/63 | 0/62 | 0/64 |
| AppendicitisInfections and infestations | 0/64 | 1/63 | 0/62 | 0/64 |
| DehydratationMetabolism and nutrition disorders | 0/64 | 1/63 | 0/62 | 0/64 |
| RashSkin and subcutaneous tissue disorders | 0/64 | 1/63 | 0/62 | 0/64 |
| PancreatitisGastrointestinal disorders | 1/64 | 0/63 | 0/62 | 0/64 |
| Angina pectorisCardiac disorders | 1/64 | 0/63 | 0/62 | 1/64 |
| Myocardial infarctionCardiac disorders | 1/64 | 0/63 | 0/62 | 0/64 |
| Back painMusculoskeletal and connective tissue disorders | 1/64 | 0/63 | 0/62 | 0/64 |
| Event | ABX464, 100mg | ABX464, 50 mg | ABX464, 25mg | Matching Placebo |
|---|---|---|---|---|
| HeadacheNervous system disorders | 27/64 | 19/63 | 13/62 | 5/64 |
| NauseaGastrointestinal disorders | 9/64 | 4/63 | 5/62 | 4/64 |
| VomitingGastrointestinal disorders | 5/64 | 2/63 | 1/62 | 1/64 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/64 | 1/63 | 1/62 | 3/64 |
| MyalgiaMusculoskeletal and connective tissue disorders | 5/64 | 0/63 | 0/62 | 0/64 |
| Abdominal pain upperGastrointestinal disorders | 4/64 | 3/63 | 3/62 | 0/64 |
| Colitis ulcerativeGastrointestinal disorders | 0/64 | 3/63 | 0/62 | 1/64 |
| NasopharyngitisInfections and infestations | 1/64 | 3/63 | 1/62 | 0/64 |
| ConstipationGastrointestinal disorders | 0/64 | 0/63 | 2/62 | 0/64 |
| DispepsiaGastrointestinal disorders | 0/64 | 0/63 | 2/62 | 0/64 |
| Age, Categorical(Participants) | ABX464 100 mg | ABX464 50 mg | ABX464 25mg | Matching Placebo | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 61 | 60 | 56 | 60 | 237 |
| >=65 years | 3 | 3 | 5 | 4 | 15 |
| Age, Continuous(Years) | ABX464 100 mg | ABX464 50 mg | ABX464 25mg | Matching Placebo | Total |
|---|---|---|---|---|---|
| Mean | 42.2 ± 12.34 | 40.2 ± 13.94 | 41.5 ± 14.16 | 41.1 ± 14.43 | 41.2 ± 13.67 |
| Sex: Female, Male(Participants) | ABX464 100 mg | ABX464 50 mg | ABX464 25mg | Matching Placebo | Total |
|---|---|---|---|---|---|
| Female | 23 | 36 | 21 | 24 | 104 |
| Male | 41 | 27 | 40 | 40 | 148 |
| Race and Ethnicity Not Collected(Participants) | ABX464 100 mg | ABX464 50 mg | ABX464 25mg | Matching Placebo | Total |
|---|---|---|---|---|---|
| Count of participants | — | — | — | — | 0 |
| Region of Enrollment(participants) | ABX464 100 mg | ABX464 50 mg | ABX464 25mg | Matching Placebo | Total |
|---|---|---|---|---|---|
| Hungary | 5 | 5 | 5 | 7 | 22 |
| Czechia | 2 | 6 | 4 | 2 | 14 |
| United States | 0 | 1 | 0 | 1 | 2 |
| Ukraine | 12 | 7 | 6 | 7 | 32 |
| Spain | 1 | 0 | 0 | 0 | 1 |
| Canada | 1 | 1 | 2 | 1 | 5 |
| Austria | 1 | 1 | 1 | 3 | 6 |
| Belgium | 4 | 2 | 0 | 2 | 8 |
| Poland | 16 | 16 | 18 | 20 | 70 |
| Italy | 5 | 2 | 6 | 7 | 20 |
| Slovakia | 3 | 7 | 5 | 3 | 18 |
| Slovenia | 1 | 1 | 1 | 0 | 3 |
| France | 8 | 8 | 7 | 7 | 30 |
| Serbia | 0 | 3 | 2 | 0 | 5 |
| Germany | 5 | 3 | 4 | 4 | 16 |
| Baseline Modified Mayo Score (MMS)(Participants) | ABX464 100 mg | ABX464 50 mg | ABX464 25mg | Matching Placebo | Total |
|---|---|---|---|---|---|
| Baseline MMS: 4 | 0 | 0 | 0 | 1 | 1 |
| Baseline MMS: 5 to 6 | 17 | 16 | 17 | 21 | 71 |
| Baseline MMS: 7 to 9 | 47 | 47 | 44 | 42 | 180 |
Showing the first 100 of 130 sites across 17 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2019 to primary completion in Apr 2021, 19 months.
Results were first posted in Nov 2025, 4 years 7 months after primary completion.
Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's 19 months is below that.
Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ABX464